Physician profile
Brian Gb Gaster
NPI 1922099639
$4,454.26
in general payments reported to CMS, 2019-2025
24 companies · $691 in 2025
The $691 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $147 · 2021: $445 · 2022: $600 · 2023: $877 · 2024: $1,365 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $664.71 | 2022-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $654.75 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $575.62 | 2022-2025 | |
| Alcon Vision LLC | $377.44 | 2020-2025 | Rocklatan, Tryptyr, Precision7 |
| Aerie Pharmaceuticals, INC. | $330.22 | 2019-2021 | |
| Allergan, INC. | $233.92 | 2019-2020 | |
| Oyster Point Pharma, INC. | $232.17 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $173.87 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $162.94 | 2022-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $154.94 | 2022-2023 | |
| Glaukos Corporation | $152.49 | 2024-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $133.91 | 2024-2025 | Xdemvy |
| Mallinckrodt Enterprises LLC | $118.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $111.12 | 2024 | Ultomiris |
| Dompe US, INC. | $78.66 | 2024 | Oxervate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $65.00 | 2024 | Vevye |
| Astellas Pharma US INC | $63.69 | 2024-2025 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $55.03 | 2021 | |
| Recordati_rare_diseases_inc. | $22.94 | 2025 | Cystadrops |
| Rxsight INC | $22.92 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Thea Pharma INC. | $22.35 | 2025 | Iyuzeh |
| Genentech USA, INC. | $18.64 | 2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $15.01 | 2023 | Syfovre |
| Rayner Intraocular Lenses Limited | $13.61 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.